key: cord-0887754-brc9paq0 authors: Orner, Erika; Rodgers, Mary A; Hock, Karl; Tang, Mei San; Taylor, Russell; Gardiner, Mary; Olivo, Ana; Fox, Amy; Prostko, John; Cloherty, Gavin; Farnsworth, Christopher W. title: Comparison of SARS-CoV-2 IgM and IgG seroconversion profiles amongst hospitalized patients in two US cities date: 2020-12-24 journal: Diagn Microbiol Infect Dis DOI: 10.1016/j.diagmicrobio.2020.115300 sha: 24f2313c3f19a9827c49910a27b93353e754187e doc_id: 887754 cord_uid: brc9paq0 BACKGROUND: The clinical and public health utility of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serologic testing requires a better understanding of the dynamics of the humoral response to infection. OBJECTIVE: To track seroconversion of IgG and IgM antibodies in patients with SARS-CoV-2 infection and its association with patient and clinical factors and outcomes. METHODS: Residual patient specimens were analyzed on the Abbott ARCHITECT i2000 instrument using the Abbott SARS-CoV-2 IgG assay and prototype SARS-CoV-2 IgM assay. Age, sex, comorbidities, symptom onset date, mortality, and specimen collection date were obtained from electronic medical records. RESULTS: 359 longitudinal samples were collected from 89 hospitalized patients 0-82 days post-symptom onset. 51.7% of patients developed IgG and IgM antibodies simultaneously; 32.8% seroconverted for IgM before IgG. On average, patients seroconverted for IgG by 8 days and for IgM by 7 days post-symptom onset. All patients achieved IgG seropositivity by 19 days and IgM seropositivity by 17 days. Median time to IgG and IgM seroconversion was prolonged and initial levels of IgG were lower in immunocompromised patients and patients <65 years of age compared to immune competent patients and those ≥65 years of age. Immunocompromised patients also had persistently lower levels of IgM that peaked on day 17.6 and decreased thereafter compared to immune competent patients. IgM seroconversion in patients who died reached significantly higher levels later after symptom onset than in those who recovered. CONCLUSIONS: SARS-CoV-2 infected patients have similar time to seroconversion for IgG and IgM. However, differences in immune status and age alter time to seroconversion. These results may help guide serologic testing application in COVID-19 management. Widespread, rapid, and accurate diagnostic testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is critical for tracking infection incidence and informing mitigation strategies to limit the spread of infection [1] . The utility of serologic testing to detect humoral immune responses to the virus-namely, the presence and levels of immunoglobulin (Ig)G, IgM, and total Ig-is an area of intense investigation. SARS-CoV-2 serologic testing may be useful for confirming diagnosis in symptomatic patients presenting outside of the window of positivity for polymerase chain reaction (PCR)-based SARS-CoV-2 tests, identifying convalescent plasma donors, evaluating immune responses and the efficacy of vaccine candidates, and establishing seroprevalence at the population level [2] [3] [4] [5] . Several studies have examined the timing of SARS-CoV-2 antibody seroconversion relative to symptom onset with discrepant results [2, 6, 7] . Differences in SARS-CoV-2 seroconversion dynamics across studies are related to assay design, including the selection of the antigen target, infection severity, or other comorbidities. Furthermore, few studies have assessed the utility of seroconversion profiles to predict infection severity or outcomes following SARS-CoV-2 infection. More information about the dynamics of the early humoral immune response is needed to realize the full potential of serological testing for SARS-CoV-2 [8, 9] . We examined IgG and IgM seroconversion in a cohort of SARS-CoV-2-infected patients. Patient residual serum and plasma samples were collected at multiple timepoints postsymptom onset and SARS-CoV-2 IgG and IgM seroconversion profiles were compared based on immune status, survival, age, and sex. Montefiore and Washington University Institutional Review boards approved the use of deidentified residual specimens and patient data. Specimens were collected as part of routine clinical care between March 21, 2020 and July 20, 2020, from patients hospitalized with a PCR- All patient specimens were analyzed on the Abbott ARCHITECT i2000 instrument using the EUA Abbott SARS-CoV-2 IgG assay and the Abbott prototype SARS-CoV-2 IgM assay, per the manufacturer's instructions. A minimum of 100 µL of residual specimen was used for each assay. While both assays are intended for qualitative determination of antibodies to SARS-CoV-2, they report a semi-quantitative signal using chemiluminescent microparticles to detect IgG and IgM binding to the SARS-CoV-2 nucleocapsid protein and spike protein, respectively. Assay results are reported as an index value of the ratio of specimen to calibrator absorbance (S/C or S/CO). Per the manufacturer's recommendations, an index value of ≥1.4 S/C indicates IgG seropositivity and ≥1.0 S/CO indicates IgM positivity. The sensitivity and specificity of the ARCHITECT IgG test [11] [12] [13] and prototype IgM test [14] have been reported previously. Seroconversion was calculated by plotting seropositive and negative timepoints in heatmaps ( Figure 1 ). Presumed seropositive days were defined as days beyond positive tests, up to 30 days. Presumed seronegative days were defined as days between symptom onset and first negative day. Percent seroconversion was calculated by totaling the number of patients with known or presumed seropositivity divided by the total number of patients. Seroconversion was calculated from the date of symptom onset. Time from PCR-positive to seroconversion was not assessed since previous studies have demonstrated a wide range from symptom-onset to ED presentation and diagnostic testing, grossly overestimating the sensitivity and time to seroconversion at early timepoints [12] . Because serological status was not assessed daily for each patient, the total number of patients with serological assay data varied each day. To plot seroconversion curves, data was transformed by multiplying the percent seroconverted for each day by the total number of patients in each group. Seroconversion plots and individual groups were compared and analyzed by Log-Rank (Mantel-Cox) test. Differences between IgG and IgM antibody levels were calculated using oneway ANOVA with a Kruskal-Wallis test and a Dunn multiple-comparison test. Normality was assessed using the D'Agostino & Pearson test. All statistical analyses were performed using Excel or GraphPad Prism (version 8.3.1, San Diego, CA). Samples were collected from patients over a mean of 12.0 days ± 10.7 (range 0 -82 days). An average of 4.1 ± 1.3 (range 1 -9) samples were collected from each patient. All patients in the study were symptomatic except for one asymptomatic patient who was hospitalized for an injury related to a fall, and was PCR positive upon admission. The average age was 63 years (range 14-93) and 59% were male (Supplementary Figure 1A) . Limited data is available assessing the kinetics of IgG and IgM seroconversion following SARS-CoV-2 infection using commercial, high-throughput assays and specimens collected longitudinally. In this study, we observed that the majority of patients developed IgG and IgM antibodies simultaneously or seroconverted for IgM slightly earlier than IgG. Our findings confirm previous studies [2, 6, 7, 14] , further define the humoral immune response to SARS- patients seroconverting to IgG before IgM. Using high-throughput IgG and IgM assays, we also observed asynchronous seroconversion of IgM and IgG; however, the median time to IgG and IgM positivity were 8 and 7 days, respectively. Similar to these findings, in a study using the same ARCHITECT IgG and prototype IgM assays, Ng et al. [14] reported simultaneous increases in IgG and IgM antibody levels in 43 PCR-positive patients. This implies that contrary results are likely related to differences in study design, sample collection, patient population, and assay design. Nonetheless, near simultaneous seroconversion of IgG and IgM is consistent with studies assessing immunity to the previous SARS-CoV during the 2002-2004 outbreak [15] . Interestingly, we confirmed previous findings [2] that a subset of patients (15.5% observed here) paradoxically seroconvert IgG before IgM. We did observe a trend towards earlier IgG and later IgM seroconversion in patients who were immune compromised as well as in patients who subsequently died, implying that differences in seroconversion may be due in part to infection severity. Few studies have examined the link between immune response and disease outcomes; our observation of a potential link between IgM seroconversion rate and signal persistence late after symptom onset in patients who subsequently died requires further study. Previous studies have assessed the antibody response to SARS-CoV-2; however, the majority have used laboratory-developed assays or clinical assays not widely available in most countries. Therefore, the findings from previous studies may not be generalizable. Our finding of higher SARS-CoV-2 antibodies in older (≥65 years of age) versus younger (<65 years of age) adults confirms a previous report that found a correlation between older age and higher SARS-CoV-2 antibody levels [16] . Similarly, Gorse et al. [17] examined IgG antibodies to 4 human coronaviruses in older (60-85 years old) and younger (21-40 years old) individuals 5 days and 3-4 weeks post-symptom onset. The authors observed significantly higher antibody concentrations in the older group during both stages, suggesting that older participants would have had a greater number of previous exposures to coronaviruses, which would prompt a larger and earlier immune response compared to younger participants. Interestingly, we also observed that patients younger than 65 years of age had a prolonged time to seroconversion and lower levels of IgG signal early (<10 days) post-symptom onset, though this difference in IgG signal did not persist over time. We also observed differences in seroconversion rate and antibody signal level over time based on patient and clinical factors, including immune status. Ng et al. reported a delay in IgG seroconversion in immunosuppressed patients (kidney transplant recipients); however, this delay was not seen in all patients who were immunosuppressed [14] . We also found a delayed time to IgG/ IgM seroconversion and lower mean levels of IgG and IgM signal in immunocompromised patients, with IgG levels peaking on day 15 and remaining elevated, while IgM signal levels decreased after peaking on day 17.6. Interestingly, of the seronegative immunocompromised patients, only 1 died from complications due to SARS-CoV-2 infection. This implies that factors secondary to antibody-mediated clearance are crucial for resolution of primary SARS-CoV-2 infections. Our study adds to a growing body of literature supporting a role for IgM testing to confirm SARS-CoV-2 infection in symptomatic patients in lieu of RNA testing, either because a patient presents after the window for PCR-based testing or because PCR testing is unavailable. Given the lack of evidence in the peer reviewed literature, the Infectious Diseases Society of America (IDSA) makes no recommendations for or against the use of SARS-CoV-2 IgM serological assays to detect past infection [18] . However, the IDSA does advocate for the use of serological testing in symptomatic patients that are persistently PCR negative [5] . Serological testing for anti-SARS-CoV-2 IgG was sufficient in the early phase of the COVID-19 pandemic to confirm diagnosis in such cases. However, as the prevalence of SARS-CoV-2 infections increases and as other seasonal respiratory infections simultaneously rise, it will be important to distinguish acute infections from past infections. To this end, the presence of IgM antibodies to SARS-CoV-2 may help reduce diagnostic uncertainty in this clinical scenario. In support of this, the majority of patients in our study had low or decreasing IgM levels 30 days post-symptom onset and 16/47 patients trending downward before day 14 post-symptom onset. While larger studies are necessary to confirm these findings, the best fit curve predicted that patients would be negative for IgM antibodies by day 37 post-symptom onset while remaining persistently positive for IgG using the assays described here. In clinical practice, the simultaneous presence of anti-SARS-CoV-2 IgM and IgG may provide evidence of recent infection (i.e., within the past 40 days), whereas the presence of IgG without IgM may imply infection >40 days prior. IgM screening may also be useful in low prevalence populations. The CDC recommends that when screening low prevalence populations, an orthogonal approach is used by which serological positives are tested with a second method to confirm the presence of anti-SARS-CoV-2 antibodies [4] . Most studies to date have focused on orthogonal testing for total Ig or IgG SARS-CoV-2 antibodies [19, 20] . To this end, an approach by which IgM and IgG are screened simultaneously and separately on a single high-throughput instrument may provide benefit [21] . Furthermore, while caution should be used when interpreting anti-SARS-CoV-2 IgM results to diagnose acute infections in the absence of IgG [22] , the high specificity reported for the assays used in this study [11] [12] [13] [14] imply that this approach may provide clinical value when testing low prevalence populations. A growing body of literature has reported associations between results by commercial serological assays and neutralizing antibody titers. Similar to the kinetics of seroconversion demonstrated here, neutralizing antibody titers rise ~2 weeks after symptom onset followed by a decline [23] [24] [25] [26] [27] . Studies have also demonstrated associations between neutralizing antibody titers correlated with those of IgG in patients with more severe COVID-19 symptoms [25, 27] and in elderly and middle-aged patients relative to younger patients [26] . Interestingly, a recent study implied a crucial role of circulating IgM for SARS-CoV-2 neutralization [28] . While further studies are needed, the seroconversion kinetics demonstrated here may have important implications for demonstrating duration and efficacy of immunity, evaluation of convalescent plasma, and vaccine development [26] . One limitation of our study is that we examined a hospitalized study population, most of whom had relatively severe symptoms, which precluded analysis of variations in immune response based on symptom severity. Further, the number of immune compromised individuals we assessed was relatively small. Lastly, the IgG and IgM assays used are qualitative; therefore, analyses based on changes in level refer to a relative increase in signal over background rather than antibody titers. Future SARS-CoV-2 serology studies with larger patient cohorts should further evaluate differences in IgG and IgM dynamic profiles based on symptom severity, comorbid conditions, and other patient and clinical factors. As PCR-based SARS-CoV-positive asymptomatic patients to examine differences in immune response dynamics and evaluate the role of serologic testing in diagnosis and prognosis. In conclusion, we demonstrate similar time to seroconversion for IgG and IgM in SARS-CoV-2-infected patients measured longitudinally. Furthermore, we identify that differences in immune status and age alter time to seroconversion. These results may help guide the effective application of serologic testing in the management of COVID-19. CWF-Conception, formal analysis, provision of study specimens, manuscript preparation. MST-Provision of study materials, manuscript preparation EO-Conception, formal analysis, provision of study specimens, manuscript preparation. 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 69 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 CDC Guidance for Expanded Screening Testing to Reduce Silent Spread of SARS-CoV-2 Antibody responses to SARS-CoV-2 in patients with COVID-19 Seroprevalence of antibodies to SARS-CoV-2 in 10 sites in the United States Interim Guidelines for COVID-19 Antibody Testing. Interim Guidelines for COVID-19 Antibody Testing in Clinical and Public Health Settings Infectious Diseases Society of America Antibody responses to SARS-CoV-2 in patients With novel coronavirus disease 2019 Profiling early humoral response to diagnose novel coronavirus disease (COVID-19) SARS-CoV-2 serology: much hype, little data The Role of Antibody Testing for SARS-CoV-2: Is There One? If You Are Immunocompromised, Protect Yourself From COVID-19 Performance characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and seroprevalence in Clinical performance of two SARS-CoV-2 serologic assays Performance characteristics of four highthroughput immunoassays for detection of IgG antibodies against SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood from the San Francisco Bay Area Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirus. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population Antibodies to coronaviruses are higher in older compared with younger adults and binding antibodies are more sensitive than neutralizing antibodies in identifying coronavirus-associated illnesses Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19: Serologic Testing Orthogonal SARS-CoV-2 serological assays enable surveillance of low-prevalence communities and reveal durable humoral immunity Evaluation of orthogonal testing algorithm for detection of SARS-CoV-2 IgG antibodies Temporal course of SARS-CoV-2 antibody positivity in patients with COVID-19 following the first clinical presentation Infectious Diseases Society of America Guidelines on the Diagnosis of COVID-19: Serologic Testing Anti-spike, antinucleocapsid and neutralizing antibodies in SARS-CoV-2 inpatients and asymptomatic individuals SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood The kinetics of viral load and antibodies to SARS-CoV-2. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. Lancet preprint Association between SARS-CoV-2 neutralizing antibodies and commercial serological assays Major role of IgM in the neutralizing activity of convalescent plasma against SARS-CoV-2 The authors thank Stacey Tobin for assistance in preparation of this manuscript.